CMX001 [444805-28-1]
Cat# B1089-5mg
Size : 5mg
Brand : APExBIO Technology
CMX001
CMX001 is a broad spectrum antiviral agent [1].
CMX001 has been reported to be active in vitro against a broad range of viruses from all five families of dsDNA viruses infecting human with EC50 values of 0.02μM, 0.0004μM, 17μM , 0.045μM and 0.07μM for Adenovirus, Herpesvirus, Papillomavirus, Polyomavirus and Orthopoxvirus, respectively. In addition, CMX001 has been revealed to arrest disease progression by inhibiting viral DNA replication and thereby reducing viral burden. Apart from these, initial studies has been demonstrated the efficacy of CMX001 for pre-exposure and post-exposure prophylaxis in mouse, rabbit, cynomolgus monkeys and human [1].
References:
[1]Lanier R1, Trost L, Tippin T, Lampert B, Robertson A, Foster S, Rose M, Painter W, O'Mahony R, Almond M, Painter G.Development of CMX001 for the Treatment of Poxvirus Infections. Viruses. 2010 Dec; 2(12):2740-2762.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 561.69 |
| Cas No. | 444805-28-1 |
| Formula | C27H52N3O7P |
| Solubility | insoluble in DMSO; insoluble in H2O; insoluble in EtOH |
| Chemical Name | [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid |
| SDF | Download SDF |
| Canonical SMILES | CCCCCCCCCCCCCCCCOCCCOP(=O)(COC(CN1C=CC(=NC1=O)N)CO)O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
| Cell lines | Human fetal brain SVG cells |
| Preparation method | The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
| Reacting condition | 0.01, 0.03, 0.07, 0.1, and 1 μM, 96 h |
| Applications | CMX001 caused a dose-dependent decrease in the number of JCV-infected cells during initial infection. In addition, CMX001 treatment resulted in a dose-dependent decrease in the number of JCV genome copies present in infected cells. |
| Animal experiment [2]: | |
| Animal models | 4-6 week-old female A/Ncr mice |
| Dosage form | Oral administration, 10 mg/kg on day 0 and 2.5 mg/kg every other-day |
| Application | Treating mice with CMX001 at a 10 mg/kg dose followed by 2.5 mg/kg doses every other-day for two weeks provided solid protection against mortality and weight loss following an intra-nasal challenge of ectromelia virus. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1]. Jiang Z G, Cohen J, Marshall L J, et al. Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures[J]. Antimicrobial agents and chemotherapy, 2010, 54(11): 4723-4732. [2]. Parker S, Touchette E, Oberle C, et al. Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model[J]. Antiviral research, 2008, 77(1): 39-49. | |